BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31930165)

  • 1. Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis.
    Jewett A; Kos J; Kaur K; Safaei T; Sutanto C; Chen W; Wong P; Namagerdi AK; Fang C; Fong Y; Ko MW
    Mol Ther Oncolytics; 2020 Mar; 16():41-52. PubMed ID: 31930165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer.
    Jewett A; Kos J; Kaur K; Turnsek TL; Breznik B; Senjor E; Wong P; Nguyen KY; Ko MW
    Crit Rev Immunol; 2020; 40(2):93-133. PubMed ID: 32749091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.
    Jewett A; Kos J; Fong Y; Ko MW; Safaei T; Perišić Nanut M; Kaur K
    Semin Cancer Biol; 2018 Dec; 53():178-188. PubMed ID: 30081230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells target and differentiate cancer stem-like cells/undifferentiated tumors: strategies to optimize their growth and expansion for effective cancer immunotherapy.
    Kaur K; Nanut MP; Ko MW; Safaie T; Kos J; Jewett A
    Curr Opin Immunol; 2018 Apr; 51():170-180. PubMed ID: 29653339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
    Kozlowska AK; Kaur K; Topchyan P; Jewett A
    Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors
    Kaur K; Topchyan P; Kozlowska AK; Ohanian N; Chiang J; Maung PO; Park SH; Ko MW; Fang C; Nishimura I; Jewett A
    Oncoimmunology; 2018; 7(5):e1426518. PubMed ID: 29721395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice.
    Kaur K; Kozlowska AK; Topchyan P; Ko MW; Ohanian N; Chiang J; Cook J; Maung PO; Park SH; Cacalano N; Fang C; Jewett A
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31878338
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice.
    Kaur K; Chen PC; Ko MW; Mei A; Senjor E; Malarkannan S; Kos J; Jewett A
    Front Immunol; 2023; 14():1132807. PubMed ID: 37197660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice.
    Kozlowska AK; Kaur K; Topchyan P; Jewett A
    Front Biosci (Landmark Ed); 2017 Jan; 22(2):370-384. PubMed ID: 27814619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoclasts and Probiotics Mediate Significant Expansion, Functional Activation and Supercharging in NK, γδ T, and CD3+ T Cells: Use in Cancer Immunotherapy.
    Kaur K; Jewett A
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice.
    Kaur K; Chang HH; Topchyan P; Cook JM; Barkhordarian A; Eibl G; Jewett A
    Front Immunol; 2018; 9():1229. PubMed ID: 29977235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
    Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
    Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and Functions.
    Kaur K; Jewett A
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice.
    Kaur K; Chang HH; Cook J; Eibl G; Jewett A
    Front Immunol; 2017; 8():1606. PubMed ID: 29255459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients.
    Kaur K; Cook J; Park SH; Topchyan P; Kozlowska A; Ohanian N; Fang C; Nishimura I; Jewett A
    Front Immunol; 2017; 8():297. PubMed ID: 28424683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.